company background image
A003090 logo

Daewoong KOSE:A003090 Stock Report

Last Price

₩20.75k

Market Cap

₩866.9b

7D

1.2%

1Y

37.6%

Updated

28 Mar, 2024

Data

Company Financials +

A003090 Stock Overview

Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea.

A003090 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for A003090 from our risk checks.

Daewoong Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Daewoong
Historical stock prices
Current Share Price₩20,750.00
52 Week High₩27,100.00
52 Week Low₩11,460.00
Beta1.28
1 Month Change-9.39%
3 Month Change0.48%
1 Year Change37.60%
3 Year Change-36.15%
5 Year Change3.75%
Change since IPO854.70%

Recent News & Updates

Recent updates

With EPS Growth And More, Daewoong (KRX:003090) Is Interesting

Apr 13
With EPS Growth And More, Daewoong (KRX:003090) Is Interesting

A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)

Mar 29
A Look At The Intrinsic Value Of Daewoong Co., Ltd. (KRX:003090)

Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Mar 14
Daewoong Co., Ltd. (KRX:003090) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly

Feb 21
Daewoong (KRX:003090) Seems To Use Debt Quite Sensibly

The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders

Jan 31
The Daewoong (KRX:003090) Share Price Has Soared 308%, Delighting Many Shareholders

Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?

Dec 04
Do Its Financials Have Any Role To Play In Driving Daewoong Co., Ltd.'s (KRX:003090) Stock Up Recently?

Shareholder Returns

A003090KR PharmaceuticalsKR Market
7D1.2%4.3%2.4%
1Y37.6%28.2%12.2%

Return vs Industry: A003090 exceeded the KR Pharmaceuticals industry which returned 28.2% over the past year.

Return vs Market: A003090 exceeded the KR Market which returned 12.2% over the past year.

Price Volatility

Is A003090's price volatile compared to industry and market?
A003090 volatility
A003090 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement5.2%
10% most volatile stocks in KR Market11.9%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A003090's share price has been volatile over the past 3 months.

Volatility Over Time: A003090's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1945348Yeong-Hwan Yoonhttps://www.daewoongholdings.com

Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd.

Daewoong Co., Ltd. Fundamentals Summary

How do Daewoong's earnings and revenue compare to its market cap?
A003090 fundamental statistics
Market cap₩866.88b
Earnings (TTM)₩152.67b
Revenue (TTM)₩1.81t

5.6x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A003090 income statement (TTM)
Revenue₩1.81t
Cost of Revenue₩883.91b
Gross Profit₩929.93b
Other Expenses₩777.27b
Earnings₩152.67b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)3.73k
Gross Margin51.27%
Net Profit Margin8.42%
Debt/Equity Ratio31.0%

How did A003090 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

3%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.